...
首页> 外文期刊>The Prostate >Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer.
【24h】

Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer.

机译:在患有前列腺癌的患者中可以检测到Th1表型的天然存在的前列腺癌抗原特异性T细胞应答。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Cytotoxic T cells (CTL) are considered one of the primary effector cell populations in antitumor immunity. Recent studies, however, have demonstrated the critical importance of helper T cells (Th), specifically interferon gamma (IFN gamma)-secreting Th1 cells, either by supporting an appropriate CTL environment or by recruiting other effector cells. We evaluated whether patients with prostate cancer have naturally occurring Th-cell responses specific for two prostate cancer-associated antigens, prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP), and whether Th1-type responses to these antigens could be detected. METHODS: Peripheral blood mononuclear cells (PBMC) were collected from 80 patients with prostate cancer and 20 male controls without prostate disease. Th-cell responses were evaluated by measuring antigen-specific proliferation. IFN gamma and IL-5 secretion in response to antigen stimulation was determined by enzyme-linked immunosorbent assay. RESULTS: T cell proliferative responses specific for PSA and PAP could be detected in patients with prostate cancer. Six percent (5/80) of patients had T cell responses specific for PSA and 11% (9/80) for PAP. T cell responses specific for PSA were more prevalent in patients with metastatic disease (P = 0.02), whereas responses specific for PAP could be detected in patients irrespective of disease stage. IFN gamma-producing Th cells, specific for both PSA and PAP, could be identified in patients with prostate cancer. CONCLUSIONS: Patients with prostate cancer can have detectable Th-cell responses specific for the prostate cancer-associated proteins PSA and PAP. The presence of antigen-specific Th1 immune responses in prostate cancer patients suggests that an immune environment capable of supporting antigen-specific CTL may exist in vivo. Prostate 47:222-229, 2001. Copyright 2001 Wiley-Liss, Inc.
机译:背景:细胞毒性T细胞(CTL)被认为是抗肿瘤免疫的主要效应细胞群体之一。但是,最近的研究表明,通过支持适当的CTL环境或募集其他效应细胞,辅助性T细胞(Th)尤其是分泌干扰素γ(IFN gamma)的Th1细胞至关重要。我们评估了前列腺癌患者是否具有针对两种前列腺癌相关抗原,前列腺特异性抗原(PSA)和前列腺酸性磷酸酶(PAP)的自然发生的Th细胞应答,以及是否可以检测到对这些抗原的Th1型应答。方法:从80例前列腺癌患者和20例无前列腺疾病的男性对照组中收集外周血单个核细胞(PBMC)。通过测量抗原特异性增殖来评估Th细胞应答。通过酶联免疫吸附测定确定响应抗原刺激的IFNγ和IL-5分泌。结果:在前列腺癌患者中可以检测到特异性针对PSA和PAP的T细胞增殖反应。 6%(5/80)的患者具有PSA特异的T细胞应答,PAP的11%(9/80)。 PSA特异的T细胞应答在转移性疾病患者中更为普遍(P = 0.02),而PAP特异的应答可在患者中检测到,而与疾病阶段无关。 PSA和PAP特异的可产生IFN的Th细胞可在前列腺癌患者中得到鉴定。结论:前列腺癌患者可具有对前列腺癌相关蛋白PSA和PAP有特异性的可检测Th细胞应答。前列腺癌患者中抗原特异性Th1免疫反应的存在表明,体内可能存在能够支持抗原特异性CTL的免疫环境。前列腺47:222-229,2001。版权所有2001 Wiley-Liss,Inc.。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号